Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 18.25
MDVN's Cash to Debt is ranked lower than
54% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. MDVN: 18.25 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 9999.00 Max: No Debt
Current: 18.25
Equity to Asset 0.68
MDVN's Equity to Asset is ranked higher than
50% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MDVN: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s Equity to Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.51 Max: 0.99
Current: 0.68
-0.02
0.99
Interest Coverage 27.60
MDVN's Interest Coverage is ranked lower than
72% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 27.60 )
Ranked among companies with meaningful Interest Coverage only.
MDVN' s Interest Coverage Range Over the Past 10 Years
Min: 12.99  Med: 10000.00 Max: 9999.99
Current: 27.6
12.99
9999.99
F-Score: 4
Z-Score: 16.12
M-Score: -1.10
WACC vs ROIC
12.24%
69.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 42.36
MDVN's Operating margin (%) is ranked higher than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. MDVN: 42.36 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s Operating margin (%) Range Over the Past 10 Years
Min: -510.27  Med: -52.35 Max: 39.67
Current: 42.36
-510.27
39.67
Net-margin (%) 25.35
MDVN's Net-margin (%) is ranked higher than
91% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. MDVN: 25.35 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s Net-margin (%) Range Over the Past 10 Years
Min: -496.58  Med: -54.45 Max: 38.91
Current: 25.35
-496.58
38.91
ROE (%) 37.22
MDVN's ROE (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. MDVN: 37.22 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s ROE (%) Range Over the Past 10 Years
Min: -862.65  Med: -99.86 Max: 105.07
Current: 37.22
-862.65
105.07
ROA (%) 22.43
MDVN's ROA (%) is ranked higher than
97% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. MDVN: 22.43 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s ROA (%) Range Over the Past 10 Years
Min: -80.48  Med: -19.78 Max: 42.39
Current: 22.43
-80.48
42.39
ROC (Joel Greenblatt) (%) 230.99
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. MDVN: 230.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -201825  Med: -5265.11 Max: 299.98
Current: 230.99
-201825
299.98
Revenue Growth (3Y)(%) 113.10
MDVN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. MDVN: 113.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 113.1
Current: 113.1
0
113.1
» MDVN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MDVN Guru Trades in Q2 2015

Steven Cohen 98,700 sh (New)
Jim Simons 795,100 sh (+83.11%)
Joel Greenblatt 250,394 sh (+66.35%)
Ken Fisher 2,400 sh (unchged)
Louis Moore Bacon Sold Out
» More
Q3 2015

MDVN Guru Trades in Q3 2015

Paul Tudor Jones 12,934 sh (New)
Steven Cohen 1,641,334 sh (+1562.95%)
Ken Fisher 6,300 sh (+162.50%)
Joel Greenblatt Sold Out
Jim Simons 694,700 sh (-12.63%)
» More
Q4 2015

MDVN Guru Trades in Q4 2015

Pioneer Investments 149,693 sh (New)
Paul Tudor Jones 127,060 sh (+882.37%)
Steven Cohen 2,002,700 sh (+22.02%)
Ken Fisher 6,615 sh (+5.00%)
Jim Simons Sold Out
» More
Q1 2016

MDVN Guru Trades in Q1 2016

Joel Greenblatt 327,094 sh (New)
Andreas Halvorsen 707,319 sh (New)
Jim Simons 207,600 sh (New)
Columbia Wanger 1,780,000 sh (New)
Paul Tudor Jones 661,185 sh (+420.37%)
Pioneer Investments 400,496 sh (+167.54%)
Ken Fisher 6,631 sh (+0.24%)
Steven Cohen 291,100 sh (-85.46%)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GMXAY, NAS:GRFS, NAS:JAZZ, NAS:ALKS, NAS:BMRN, OTCPK:NVZMY, NAS:DYAX, NAS:SGEN, OTCPK:UCBJF, NAS:INCY, NYSE:OPK, OTCPK:SBMFF, NAS:ALNY, NAS:UTHR, NAS:ANAC, NAS:JUNO, NAS:ACAD, NAS:TECH, OTCPK:BTGGF, NAS:ICPT » details
Traded in other countries:WMD.Germany,
Medivation Inc is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer's disease and Huntington disease.

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history
P/E(ttm) 39.30
MDVN's P/E(ttm) is ranked lower than
61% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. MDVN: 39.30 )
Ranked among companies with meaningful P/E(ttm) only.
MDVN' s P/E(ttm) Range Over the Past 10 Years
Min: 20.81  Med: 36.71 Max: 330.65
Current: 39.3
20.81
330.65
Forward P/E 43.29
MDVN's Forward P/E is ranked lower than
86% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.70 vs. MDVN: 43.29 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.56
MDVN's PE(NRI) is ranked lower than
61% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. MDVN: 39.56 )
Ranked among companies with meaningful PE(NRI) only.
MDVN' s PE(NRI) Range Over the Past 10 Years
Min: 20.96  Med: 36.73 Max: 325.93
Current: 39.56
20.96
325.93
Price/Owner Earnings (ttm) 30.03
MDVN's Price/Owner Earnings (ttm) is ranked higher than
53% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 32.22 vs. MDVN: 30.03 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDVN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.21  Med: 34.33 Max: 1456.67
Current: 30.03
3.21
1456.67
P/B 10.35
MDVN's P/B is ranked lower than
87% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. MDVN: 10.35 )
Ranked among companies with meaningful P/B only.
MDVN' s P/B Range Over the Past 10 Years
Min: 4.74  Med: 35.60 Max: 2053.33
Current: 10.35
4.74
2053.33
P/S 9.58
MDVN's P/S is ranked higher than
54% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. MDVN: 9.58 )
Ranked among companies with meaningful P/S only.
MDVN' s P/S Range Over the Past 10 Years
Min: 4.43  Med: 21.24 Max: 650
Current: 9.58
4.43
650
PFCF 31.99
MDVN's PFCF is ranked lower than
59% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 26.08 vs. MDVN: 31.99 )
Ranked among companies with meaningful PFCF only.
MDVN' s PFCF Range Over the Past 10 Years
Min: 2.96  Med: 33.62 Max: 260.74
Current: 31.99
2.96
260.74
POCF 29.30
MDVN's POCF is ranked lower than
61% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 22.99 vs. MDVN: 29.30 )
Ranked among companies with meaningful POCF only.
MDVN' s POCF Range Over the Past 10 Years
Min: 2.96  Med: 30.79 Max: 206.47
Current: 29.3
2.96
206.47
EV-to-EBIT 22.18
MDVN's EV-to-EBIT is ranked lower than
53% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. MDVN: 22.18 )
Ranked among companies with meaningful EV-to-EBIT only.
MDVN' s EV-to-EBIT Range Over the Past 10 Years
Min: -650.3  Med: -24.20 Max: 157.5
Current: 22.18
-650.3
157.5
EV-to-EBITDA 21.75
MDVN's EV-to-EBITDA is ranked lower than
57% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. MDVN: 21.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDVN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1185.6  Med: -24.60 Max: 144.7
Current: 21.75
-1185.6
144.7
Shiller P/E 1444.09
MDVN's Shiller P/E is ranked lower than
98% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 54.39 vs. MDVN: 1444.09 )
Ranked among companies with meaningful Shiller P/E only.
MDVN' s Shiller P/E Range Over the Past 10 Years
Min: 895.5  Med: 1316.00 Max: 1611.33
Current: 1444.09
895.5
1611.33
Current Ratio 4.17
MDVN's Current Ratio is ranked lower than
52% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. MDVN: 4.17 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.81 Max: 27.3
Current: 4.17
1.46
27.3
Quick Ratio 4.17
MDVN's Quick Ratio is ranked higher than
50% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. MDVN: 4.17 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.81 Max: 27.3
Current: 4.17
1.46
27.3
Days Sales Outstanding 68.34
MDVN's Days Sales Outstanding is ranked lower than
54% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. MDVN: 68.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.21  Med: 94.91 Max: 143.37
Current: 68.34
34.21
143.37

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 94.06
MDVN's Price/Net Current Asset Value is ranked lower than
98% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. MDVN: 94.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDVN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.88  Med: 34.82 Max: 364
Current: 94.06
2.88
364
Price/Tangible Book 41.15
MDVN's Price/Tangible Book is ranked lower than
96% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. MDVN: 41.15 )
Ranked among companies with meaningful Price/Tangible Book only.
MDVN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.3  Med: 13.70 Max: 1281.11
Current: 41.15
0.3
1281.11
Price/Projected FCF 6.32
MDVN's Price/Projected FCF is ranked lower than
65% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. MDVN: 6.32 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.65  Med: 8.06 Max: 110.11
Current: 6.32
1.65
110.11
Price/Median PS Value 0.47
MDVN's Price/Median PS Value is ranked higher than
82% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. MDVN: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.83 Max: 10.5
Current: 0.47
0.2
10.5
Price/Graham Number 8.66
MDVN's Price/Graham Number is ranked lower than
89% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. MDVN: 8.66 )
Ranked among companies with meaningful Price/Graham Number only.
MDVN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.57  Med: 6.39 Max: 22.41
Current: 8.66
0.57
22.41
Earnings Yield (Greenblatt) (%) 4.51
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. MDVN: 4.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 3.20 Max: 8.4
Current: 4.51
0.6
8.4

More Statistics

Revenue (TTM) (Mil) $996.6
EPS (TTM) $ 1.45
Beta1.43
Short Percentage of Float2.63%
52-Week Range $26.41 - 62.94
Shares Outstanding (Mil)164.62

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 929 1,197 1,481
EPS ($) 1.40 2.07 2.80
EPS w/o NRI ($) 1.40 2.07 2.80
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:MDVN

Headlines

Articles On GuruFocus.com
Steven Cohen Trims Nike, Coach, Alphabet May 20 2016 
Stocks Fisher Investments Has Bought for Past 2 Quarters May 03 2016 
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 

More From Other Websites
MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2016
Glass Lewis urges Medivation shareholders to support current board Jun 24 2016
Glass Lewis Recommends Medivation's Stockholders Support the Company's Current Board Jun 24 2016
Glass Lewis Recommends Medivation’s Stockholders Support the Company’s Current Board Jun 24 2016
3:11 am Medivation sends letter to shareholders; reiterates call for stockholders to reject Sanofi's... Jun 24 2016
Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi's Misleading Claims Jun 23 2016
Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi’s Misleading Claims Jun 23 2016
Sanofi's Likely Sweetener for Medivation Panned Jun 23 2016
Sanofi Said to Consider Adding Future Payments to Medivation Bid Jun 22 2016
NIH won't cut price of taxpayer-funded prostate cancer drug Jun 20 2016
NIH won't cut price of taxpayer-funded prostate cancer drug Jun 20 2016
BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced Jun 17 2016
Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study Jun 17 2016
Medivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse... Jun 16 2016
Medivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse... Jun 16 2016
MEDIVATION INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating Medivation, Inc. For... Jun 14 2016
Medivation Has a Good Case for Patience Jun 14 2016
MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 13 2016
Medivation Urges Shareholders to Reject Sanofi Proposal Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)